A majority of top cancer centers in the United States are experiencing a shortage of the chemotherapy drugs carboplatin and cisplatin. Shortages like this can lead to delays in treatment, worse patient outcomes, and force patients to switch to different treatment options.
Unprecedented shortages of key cancer drugs in the United States could disrupt treatment for tens of thousands of patients with various forms of the disease in the coming months unless hospitals take action, experts say.
Shortages of Pluvicto, BCG, and injectable methotrexate, cisplatin, and fluorouracil are forcing some cancer patients to take less-effective treatments or wait, potentially endangering their lives.